Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events ( · people with mild/moderate/severe/critical COVID‐19

Sarilumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.12 [0.97, 1.28]
4 studies · 860 participants
Low

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.09 [0.97, 1.21]
6 studies · 2936 participants
Low